Expert Review of Pharmacoeconomics & Outcomes Research

Expert Review of Pharmacoeconomics & Outcomes Research is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy and Economic and Financial Impacts of Cancer, together about 48.8% of its articles. Its main subfields are Economics and Econometrics. (generated from OpenAlex topic counts and CAS ranking data)

Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.

Source: LetPub

Research area (LetPub): HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CAS Journal Ranking

Database indexing

SCIESSCIScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

2.28LetPub · 2026-09-13

CiteScore 2026-06

3.4LetPub · 2026-09-13

SJR 2026-06

0.51LetPub · 2026-09-13

SNIP 2026-06

0.66LetPub · 2026-09-13

h-index

41LetPub · 2026-09-13

h-index

81OpenAlex · 2026-10-01

i10-index

852OpenAlex · 2026-10-01

2-year mean citedness

1.92OpenAlex · 2026-10-01

Self-citation rate

4.5%LetPub · 2026-09-13

Share of gold OA articles

11.59%LetPub · 2026-09-13

Volume

Articles per year

121LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

6–12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

No source has fee information yet; check the journal's website.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Publisher

Taylor and Francis Ltd.

Country or region

ENGLAND

Language

English

ISSN

1473-7167

Electronic ISSN

1744-8379

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗LetPub